Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

e trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the in
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... ALEXANDRIA, Va. , May 22, 2013  Viral hepatitis ... More than 75 percent of those with hepatitis C are ... and C Testing and Awareness Day in the U.S. House ... pm in the Rayburn Foyer of the Rayburn House Office ... The American Association for the Study of Liver Diseases ...
(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...
(Date:5/22/2013)... CAESAREA, Israel , May 22, 2013 ... clinical data presented from the DEFLECT-I study demonstrates that ... brain lesion volume during TAVR (Transcatheter Aortic Valve Replacement) ... Heart Scientific Advisory Board announces consensus on the importance ... the importance and need for cerebral protection during cardiovascular ...
Breaking Medicine Technology:Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 2New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 3New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR 4
... Sept. 13 COPAN announced this week that it ... flocked swabs, FLOQSwabs, for collection and transfer of biological ... latest addition to a growing number of patents held ... flocked swabs for collection and transfer of biological samples, ...
... "Dan Rather Reports" will present an investigation into the ... drugs like Viagra or Cialis, these are counterfeit versions ... treatment of Alzheimer,s and Casodex, used to treat prostate ... for criminals while, potentially robbing unsuspecting victims of something ...
Cached Medicine Technology:COPAN Secures Japanese Patent for its Flocked Swab Innovation 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 3Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 4Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 5
(Date:5/23/2013)... (PRWEB) May 23, 2013 Ezell Law ... in practice. For 25 years, Jeff Ezell has ... advice with a focus on personal injury cases ... worked for insurance companies, he offers clients a uniquely ... companies operate, which enables him better serve his clients. ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Greenville ... that all team members and doctors have recently ... professional rescuer with an Automated External Defibrillator (AED). ... (AED) is a medical device designed to analyze ... to victims of ventricular fibrillation to restore the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 OnSomble, Inc. ... nurse understanding of the professional role and empower nurses ... Joy, vice president of patient care services and chief ... nurses are excellent clinicians, and we want to help ... them that to lead they must follow, encourage them ...
(Date:5/23/2013)... Better Life Maids of Portland Oregon is putting ... its one of a kind green house cleaning service in ... completed May 29th, and a soft opening scheduled for June ... training in Portland recently and will travel to St. Louis ... "It really is a lot to take in" stated Heather ...
(Date:5/23/2013)... PhD Box has introduced a ... the research process by offering assistance for Thesis Proposals. The ... of services that the company provides for research consultation in ... dedicated proposal writing service is that this is the stage ... research process find it difficult to draft a proposal as ...
Breaking Medicine News(10 mins):Health News:Ezell Law Firm Celebrates 25 Years in Practice 2Health News:Greenville Oral & Maxillofacial Surgeons Announce CPR Re-Certification 2Health News:OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2Health News:PhD Box Unveils Proposal Writing Services for Research Scholars 2
... ... that wish to host continuing medical education courses at their medical facility in 2010. This ... well as reduce their overall costs to educate their physical therapy and occupational therapy team ... ...
... OAKLAND, Calif., Dec. 4 Herpes zoster, also known as ... against chicken pox, according to a Kaiser Permanente study in ... , The study, the largest of its kind, used ... with the varicella (chicken pox) vaccine from 2002 to 2008 ...
... Dec. 3 The Cancer Center at Harrington ... announced today. , "We expect to start seeing patients immediately," ... , The approval was granted today by the Massachusetts Department ... the facility. , The opening of The Cancer Center ...
... , CHICAGO, Dec. 3 ... United States District Court for the Southern District of ... disclosed $350 million settlement that would resolve a class-action ... the AMA, Medical Society of the State of New ...
... outperforms widely used sulfonylureas, but each patient will be different, ... A class of drugs still taken by millions of people ... of dying and heart failure than the newer treatment metformin, ... diabetes treatment, performed less well than metformin in a study ...
... ... ... nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) vaccination clinics ... Crystal Lake and McHenry and will be open as follows: ,   ...
Cached Medicine News:Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 2Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 3Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2Health News:Diabetes Drugs Go Head-to-Head in Study 2Health News:Diabetes Drugs Go Head-to-Head in Study 3Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4
... easy, breezy, beautiful image to its eyewear ... of stylish colors, trendy shapes, spring hinges, ... to target the broad demographics of the ... fashionable frames. The Cover Girl Eyewear collection ...
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... The license agreement between Brook Brothers ... 1993. Characterized by lightweight materials and ... collections reflect the unique features of ... A product with classic style and ...
... debuted in 1937 with the Aviator style ... to Luxottica Group's brand portfolio in 1999. ... celebrities since day one, Ray-Bans styles are ... best-selling sunglasses in the world. Characterized by ...
Medicine Products: